41 results about "CD8A" patented technology

The invention discloses a chimeric antigen receptor hCD19scFv-CD8a-CD-28-CD3zata and application thereof. The chimeric antigen receptor is serially connected by an anti-human CD19 monoclonal antibody H119a light chain and heavy chain variable region (hCD19scFv), human CD8a hinge region, a human CD28 transmembrane region, an intracellular region and a human CD3zata intracellular region. The chimeric antigen receptor is used for modifying T lymphocyte, and the modified T lymphocyte (CAR-T cell) can be used for treating the tumor with positive surface CD19.

The invention provides a BCMA-based (B cell maturation antigen-based) chimeric antigen receptor, comprising following cis-form cascade domains: CD8a leader region, scFv fragment BCMA scFv of anti-BCMA antibody, CD8a hinge region and transmembrane region, CD28 intracellular signal domain and CD3 Zeta intracellular signal domain; the CD3 Zeta intracellular signal domain is wild CD3 Zetaintracellular signal domain or mutant CD3 Zeta mut intracellular signal domain; the BCMA-based chimeric antigen receptor can enhance anti-apoptotic capability of T-cells and enhance CAR T-cell and antigen bonding and signal conduction; T-cells with the BCMA-based chimeric antigen receptor show good tumor targeting performance in in-vivo experiments, tumors diminish significantly after two weeks of dosage, and the T-cells have excellent therapeutic effect in vivo.

The invention provides an anti-tumor NK cell, and a preparation method and application thereof. The anti-tumor NK cell is an NK cell edited by a chimeric antigen receptor. The chimeric antigen receptor comprises an extracellular domain fragment of PD-1, an F2A peptide fragment, the extracellular region of a CD8a signal peptide, the extracellular variable region of a single-chain antibody capable of recognizing and binding to HER2 protein, a CD8 alpha Linker region, a CD28 transmembrane and intracellular synergistic co-stimulation region, and a CD3 zeta fragment for intracellular signal transmission. The NK cell disclosed by the invention can express a CAR element targeting HER2 on a cell membrane and express secretory PD-1 protein at the same time, so the binding of PD-1 and PD-L1 is blocked, and the killing function of the NK cell is increased; and the anti-tumor NK cell is used for preparing anti-tumor drugs, can target tumor cells and enhance cytotoxic effect, is low in immunogenicity, easily realizes response and activation and can achieve allogeneic reinfusion, and the tumor killing effect of the NK cell is remarkably improved.

The invention discloses a specific chimeric antigen receptor (anti-BCMA scFv-CD8a-41BB-CD3 zeta) for human BCMA and application thereof. The chimeric antigen receptor is formed by a single-chain-antibody anti-BCMA scFv, a hinge region, a transmembrane region and an intracellular region in series. The chimeric antigen receptor is used for modifying human T lymphocyte, and the modified T lymphocyteis used for prevention and treatment of surface BCMA positive tumor and preparing of antitumor medicines.

The present invention relates to the field of cellular immunotherapy for tumors and, more particularly, to a recombinant plasmid for the construction of recombinant malaria parasites and their use, wherein the recombinant plasmid is a tumorigenin-specific antigen gene inserted into the pL0017 plasmid, Recombinant malaria parasite, comprising the recombinant plasmid. Compared with plasmid DNA and RNA vector, the recombinant malaria parasite can be multiplied by the proliferation of Plasmodium, which is beneficial to the increase of the antigen in vivo. Compared with the defective virus and bacterial carrier, it survives in the red blood cells of the body longer, not short-term by the body's immune system to clear, long-term effective expression of exogenous tumor antigen, is conducive to long-term antigen and immune stimulation. The recombinant malaria parasite is capable of activating the high expression of Th1-related cytokines in vivo and increasing the proportion of CD8a + DCs in total CD11c + DCs and further activating specific cytotoxic T lymphocyte responses against tumor antigens, which is beneficial to the antitumor effect of the vaccine.

The invention belongs to the technical field of tumor biological products, and discloses a chimeric antigen receptor, a gene thereof, a recombinant expression vector, an engineered HER2 targeting NKTcell, and an application of the NKT cell. The chimeric antigen receptor is HER2ScFv-CD8-CD137-CD3zeta and comprises a CD8a signal peptide, HER2ScFv, a hinge region and transmembrane region for shortening CD8, an intracellular signal structural domain of CD137, and an intracellular signal structural domain of CD3zeta which are in series. The CARHER2-NKT cell provided by the invention has a certaintherapeutic effect on epithelial tumors when used for curing advanced HER2 positive epithelial tumors

The invention discloses an optimized chimeric antigen acceptor DAP12-T2A-CD8a-CD19scfv-NKp44 and application thereof. The chimeric antigen acceptor is formed by serially connecting an intracellular second conduction structural domain DAP12, T2A, a CD8a signal peptide, an anti-human CD19 monoclonal antibody FMC63 light-chain and heavy-chain variable region CD19scFv, and an intracellular first conduction structural domain. The chimeric antigen acceptor is used for modifying T lymphocyte, and the modified T lymphocyte (CAR-T cells) can be used for treatment of CD19 positive hematologic malignancy. In a hematologic malignancy killing test, killing capacity of the CAR-T cells to leukemia tumor cells are obviously enhanced, and good safety and anti-tumor activity are shown in the clinical application.

The invention relates to the technical field of medical diagnosis, and specifically relates to an X-linked lymphoproliferative syndrome diagnostic kit and application thereof. The kit comprises anti-human CD 3, CD56, CD8a and SAP flow fluorescent antibodies, an isotype control fluorescent antibody of the anti-human SAP flow fluorescent antibody, an anti-human SAP Western Blot antibody, and a secondary antibody corresponding to the anti-human SAP Western Blot antibody. A method for detecting SAP protein abundance in CTL and NK cells based on the diagnostic kit is quick to detect, high in flux, high in accuracy, and small in human factor influence.

The invention belongs to the technical field of tumor cell immunotherapy, and particularly relates to a restriction-type CAR capable of inhibiting the dryness of tumor cells and application of the CAR. The chimeric antigen receptor is an amino acid sequence obtained by connecting a plurality of protein fragments, and is obtained by sequentially connecting a human CD8a molecule signal peptide CD8a,a human NKG2D extracellular region, a human CD8 molecule transmembrane region and a 41BB molecule intracellular region 41BB, and a human CD3z molecule intracellular region CD3Zeta. In the preferred design, the chimeric antigen receptor is further obtained by connecting a connecting sequence to an IL24 CDS region sequence IL24. By further optimizing the structure of the CAR and simultaneously in combination with SFN application, the chimeric antigen receptor has good technical effects on effectively killing tumor cells and tumor stem cells, reducing the recurrence of diseases and improving theapplication effect of CAR-T cells, so that the has good practical value and popularization and application significance.

The invention belongs to the field of tumor biological products, and discloses a chimeric antigen receptor and a gene thereof and a recombinant expression vector of the gene as well as a CAR133-NKT cell and a preparation method and application of the CAR133-NKT cell. The chimeric antigen receptor is CD133ScFv-CD8-CD137-CD3 zeta including tandem a CD8a signal peptide, a CD133ScFv, CD8 hinge and transmembrane regions, a CD137 intracellular signal domain and a CD3 zeta intracellular signal domain. The CAR133-NKT cell provided by the invention has very good specific killing activity against a CD133-positive epithelial tumor cell when co-culture is performed with the CD133-positive epithelial tumor cell; and the CAR133-NKT cell provided by the invention has a certain therapeutic effect on an epithelial tumor when treating the CD133-positive epithelial tumor.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The invention is based, at least in part, on the discovery that an immune-score expression level based on one or more of PD-L1, CXCL9, IFNG, GZMB, CD8A, and PD-1 in a sample obtained from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)).

The present invention provides a method for predicting the treatment response to anti-cancer immunotherapy of a mammalian cancer patient, the method comprising: a) measuring the gene expression of at least 2 the following cancer promoting genes: PTGS2, VEGFA, CCL2, IL8, CXCL2, CXCL1, CSF3, IL6, IL1B and IL A in a sample obtained from the tumour of the patient; b) measuring the gene expression of at least 2 of the following cancer inhibitory genes: CXCL11, CXCL10, CXCL9, CCL5, TBX21, EOMES, CD8B, CD8A, PRF1, GZMB, GZMA, STAT1, IFNG, IL12B and IL12A in a sample obtained from the tumour of the patient; c) computing a ratio of the gene expression of said at least 2 cancer promoting genes and the gene expression of said at least 2 cancer inhibitory genes; and d) making a prediction of the treatment response and / or prognosis of the patient based on the gene expression ratio computed in step c). Also provided are related methods for stratifying patients and for treating patients, including with immune checkpoint blockade therapy.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The compositions and methods described herein can be used, for example, to determine the propensity of a patient to benefit from treatment with a PD-L1 axis binding antagonist and to treat such patients accordingly. Using the compositions and methods of the disclosure, a patient, such as a human cancer patient, may be determined to be likely to benefit from treatment with a PD-L1 axis binding antagonist if the patient exhibits an elevated pre-treatment expression level of one or more of CST7, NKG7, GZMH, MT-ND4, HLA-H, CCL5, CD8A, CMC1, CD8B, HCST, MT-CYB, MT-ND4L, KLRG1, MT-CO2, MT-ATP6, PLEK, CTSW, HLA-C, LYAR, LITAF, GZMB, KLRD1, FGFBP2, KLRC4-KLRK1, KLRK1, B2M, GZMA, ID2, CX3CR1, PRSS23, GNLY, PRF1, and PATL2. Exemplary PD-L1 axis binding antagonists that may be used in conjunction with the compositions and methods of the disclosure are PD-L1 binding antagonists, such as anti-PD-L1 antibodies and antigen-binding fragments thereof, including atezolizumab, as well as PD-1 binding antagonists, such as anti-PD-1 antibodies and antigen-binding fragments thereof.

The invention provides a single-chain antibody targeting c-Met, a chimeric antigen receptor, a recombinant vector, a CAR-T cell and an application thereof, and belongs to the technical field of tumortherapy, and the amino acid sequence of the single-chain antibody is shown as one of SEQ ID No. 1 to SEQ ID No. 3; wherein the chimeric antigen receptor comprises a CD8a signal peptide, a Flag label,the single-chain antibody, a CD8a hinge region-transmembrane region, a 4-1BB functional region and a CD3 functional region which are connected in sequence; the chimeric antigen receptor targeting c-Met can be highly specifically combined with a c-Met antigen, T cells modified by the chimeric antigen receptor targeting c-Met can efficiently kill c-Met high-expression tumor cells in a targeting manner, and ideal curative effects are achieved in vivo and in vitro.

The invention belongs to the technical field of tumor immunotherapy, and particularly relates to a CXCL9 modified chimeric antigen receptor T (CAR-T) structure and application patent application matter thereof. The CXCL9 modified CAR-T structure meso-CAR-CXCL9 has a specific structure: CD8a-meso-CD28-CD3Zeta-P2A-CXCL9. In the application, inventors obtain CAR-T-CXCL9 cells based on mesothelin design by taking a lung cancer model as an example. Preliminary experiment results show that, compared with conventional CAR-T cells, the modified cells have higher cytokine secretion and cytotoxicity capacities, can obviously increase immune cell infiltration of a tumor site, and inhibit angiogenesis, and further, the modified CAR-T-CXCL9 cell therapy slows down tumor growth, increases the survival rate of mice, and shows excellent anti-tumor activity.

The invention relates to a screening method of a tumor immunotherapy prognosis marker. The screening method comprises the following steps: acquiring expression data, mutation data and clinical curative effect data of a candidate gene group of cancer species to be analyzed; performing statistical independence test on the mutation condition of the candidate gene group and the expression condition ofan immune genome, finding out gene mutation related to the immune genome, and sorting genes in the candidate gene group according to association degrees from high to low, wherein the immune genome comprises CD8A, GZMA, GZMB, IFN [gamma], EOMES, CXCL9, CXCL10, and TBX21; dividing the first N genes into a mutation group and a non-mutation group according to whether the first N genes are mutated ornot, performing survival analysis, and selecting M genes with most significant differences for reservation according to log-rank changes; validating the resulting genes in independent datasets to determine mutation and prognostic correlation thereof.

The invention discloses a PSMA-targeted macrophage membrane-wrapped bionic nano-drug carrier and application, a nanogold carrier is wrapped by a macrophage membrane, and a PSMA-targeted antibody based on a sequence as shown in SEQ.ID.NO.1 is expressed on the macrophage membrane in a transmembrane manner; the antibody is a gy-1 single-chain antibody, and is expressed on a macrophage cell membrane in a transmembrane manner through fusion expression with a CD8a hinge region and a CD8a transmembrane region. The preparation method comprises the following steps: constructing a lentiviral vector for expressing a transmembrane single-chain antibody by utilizing a genetic engineering method, packaging into lentivirus, infecting macrophages to express the transmembrane single-chain antibody, and extracting a cell membrane to carry out bionic modification on a nano-vector; the prepared nano-carrier is expected to overcome the two problems of strong exogenous property and weak targeting property of the traditional nano-drug carrier, and can be used for preparing targeted diagnosis and treatment reagents and drugs for prostatic cancer.

The present invention provides a method for predicting the treatment response to anti-cancer immunotherapy of a mammalian cancer patient, the method comprising: a) measuring the gene expression of atleast 2 the following cancer promoting genes: PTGS2, VEGFA, CCL2, IL8, CXCL2, CXCL1, CSF3, IL6, IL1B and IL1A in a sample obtained from the tumour of the patient; b)measuring the gene expression of atleast 2 of the following cancer inhibitory genes: CXCL11, CXCL10, CXCL9, CCL5, TBX21, EOMES, CD8B, CD8A, PRF1, GZMB, GZMA, STAT1, IFNG, IL12B and IL12A in a sample obtained fromthetumour of the patient; c) computing a ratio of the gene expression of said at least 2 cancer promoting genes and the gene expression of said at least 2 cancer inhibitory genes; and d) making a prediction of the treatment response and / or prognosis of the patient based on the gene expression ratio computed in step c). Also provided are related methods for stratifying patients and for treating patients, including withimmune checkpoint blockade therapy.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The invention is based, at least in part, on the discovery that an immune-score expression level based on one or more of PD-L1, CXCL9, IFNG, GZMB, CD8A, and PD-1 in a sample obtained from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)).

The invention discloses an immunoglobulin A nephropathy T cell diagnostic marker. On the first aspect, the invention provides application of a reagent for quantitatively detecting at least one of the following markers in preparation of the diagnostic kit for IgA nephropathy: CCR3, CD4, CD8A, GATA3, GZMA, HDAC7, RORA and VEGFC. According to the application disclosed by the embodiment of the invention, the application at least has the following beneficial effects that the pathogenesis of the immunoglobulin A nephropathy is related to five gene axes (Axis), screening is carried out from related mRNA gene expression data based on a specific gene or protein of a T cell from the T cell immune axis (T Cell Immunity Axis) to obtain the eight markers, and the immunoglobulin A nephropathy can be used for detecting the immunoglobulin A nephropathy. Whether a subject suffers from IgA nephropathy or not can be efficiently and accurately diagnosed through quantitative detection on the basis of at least one of the eight markers, and good specificity and sensitivity are achieved.

Disclosed herein are methods of detecting and treating checkpoint inhibitor responsive cancers comprising calculating, determining, or obtaining PD-L1 expression, CD8A expression, and tumor content from a cancer specimen.

The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof, wherein the subject is identified as having a high inflammatory gene signature score. In some embodiments, the high inflammatory gene signature score is determined by measuring the expression of a panel of inflammatory genes in a tumor sample obtained from the subject, wherein the inflammatory gene panel comprises CD274 (PD-L1), CD8A, LAG3, and STAT1.

The invention relates to a method for preparing CAR-T (chimeric antigen receptor T) cells, which comprises the following steps of: synthesizing plasmids which are composed of a CD19 single-chain variable region, a CD8a hinge region, a CD8a transmembrane region, a 4-1BB signal, a CD3 zeta inclusion signal, an IL-7 sequence and a CCL17 sequence; packaging the virus to obtain a lentivirus concentrated solution, and measuring the virus titer of the lentivirus concentrated solution; and preparing T cells, namely activating, transducing and amplifying the prepared T cells which are CD8 < + > T cells, and harvesting CAR-T cells. The invention also relates to a method for preparing the T cell. The invention has excellent effects as described in the specification.

The invention relates to a trophoblast, a preparation method thereof and application of the trophoblast in massive rapid amplification of gamma delta T cells. The preparation method comprises the following steps: S1, constructing a pLenti-okt3-CD64-CD86-4.1BBL lentiviral plasmid vector; S2, packaging lentiviral particles by using the pLenti-okt3-CD64-CD86-4.1BBL plasmid vector; S3, preparing K562-okt3-CD64-CD86-4.1BBL trophoblast; S4, obtaining buffy coat cells of umbilical cord blood; and S5, carrying out in vitro amplification on gamma delta T cells of the umbilical cord blood. According tothe preparation method, an okt3 single-chain antibody is expressed on a trophoblast membrane through a CD8A transmembrane region, especially, the gamma delta T cells can be rapidly and massively amplified from the umbilical cord blood at low cost, the amplification multiple of the gamma delta T cells can reach about 10000 times after a 24-day amplification period, and the purity of the prepared gamma delta T cells can reach 90% or above. Compared with stimulation by a soluble okt3 antibody, the membrane-bound okt3 has the amplification multiple over 2 times to the gamma delta T cells, and hasa good clinical application prospect.

The invention provides a kit for simultaneously detecting various cell subpopulations and functional changes and application of the kit. The kit comprises an antibody composition, and the antibody composition comprises a surface antibody composition and an intracellular antibody composition. The surface antibody composition comprises a combination of at least two of Zombie NIR, CD45, Ly6G, CD11b, F4 / 80, Ly6c, NK1.1, CD3, CD4, CD25, CD8a, CD19, CD11c, CD80 and CD206. The intracellular antibody composition comprises a combination of at least two of FoxP3, IL-10, Granzyme B, Perforin and IFNgamma. The invention also provides a method for detecting the change of the immune cell subpopulations. The kit can be used for simultaneously detecting changes of a plurality of immune cell subgroups and functions, and the result is comprehensive and specific.